LAGEVRIO molnupiravir 200 mg capsules bottle, Merck Sharp & Dohme (Australia) Pty Ltd, CON-1182
Product name
LAGEVRIO molnupiravir 200 mg capsules bottle
Sponsor name
Merck Sharp & Dohme (Australia) Pty Ltd
Batches
CKFWW, CKGHW, CKSFM, CKFWV, CKFXD and CKFXF
Consent start
Consent no.
CON-1182
Duration
The consent is effective from 17 November 2023 until 29 February 2024.
Standard
of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product labels are international labels.
Conditions imposed
1. The product must be supplied with the labels that were considered and agreed to as part of the evaluation under section 25 of the Therapeutic Goods Act 1989, being&%2358;a. The international label in submission as provided i. Carton labelii. Blister label
Import, Supply, &/or Export
supply
Therapeutic product type
Prescription medicines
This webpage on the TGA website was printed on 14 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/section-14-consents/lagevrio-molnupiravir-200-mg-capsules-bottle-merck-sharp-dohme-australia-pty-ltd-con-1182